Priti Hegde: I’m honored to become a member of the Kite team and build on their tremendous success in autologous CAR T-cell therapy, while advancing the next-generation of cell therapy research.
Priti Hegde, Senior Vice President and Global Head of Kite Research, shared a post by Kite Pharma on LinkedIn:
“Cell therapy has transformed cancer care in heme malignancies. There has never been a more exciting time in this field, as the science rapidly evolves to include new platforms and the clinical potential extends to earlier lines of therapy, solid tumors and even disease areas beyond oncology.
I’m honored to become a member of the Kite team and build on their tremendous success in autologous CAR T-cell therapy, while advancing the next generation of cell therapy research.”
Quoting Kite Pharma on LinkedIn:
“We’re pleased to welcome Priti Hedge, PhD, as Senior Vice President and Global Head of Kite Research.”
Source: Priti Hedge/LinkedIn and Kite Pharma/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023